Recent progress in the research on the molecular biology of lung cancer revealed that the
clinical response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …

Somatic mutations in the epidermal growth factor receptor (EGFR) have been identified in
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …

Discovery of sensitizing mutations in epidermal growth factor receptor (EGFR) and the
subsequent development of EGFR tyrosine kinase inhibitors (TKIs) have substantially …

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small-cell lung
cancer (NSCLC) cases comprise approximately 85% of the lung cancer cases. Before the …

Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …

The presence of activating gene mutations in the epidermal growth factor receptor of non-
small cell lung cancer patients is predictive (improved progression-free survival and …

Lung cancers with an epidermal growth factor receptor (EGFR) gene mutation account for~
40% of adenocarcinomas in East Asians and~ 15% of those in Caucasians and African …

The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …

Non-small cell lung cancer (NSCLC) tumors with specific mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been defined as 'oncogene addicted'to indicate …

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)
mutations derive greater benefits from first-and second-generation tyrosine kinase inhibitors …